Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 3
1995 1
2009 1
2010 1
2012 2
2013 2
2014 3
2015 2
2016 2
2017 5
2018 1
2019 1
2020 3
2021 4
2022 2
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
Koudonas A, Papaioannou M, Kampantais S, Anastasiadis A, Hatzimouratidis K, Dimitriadis G. Koudonas A, et al. Medicine (Baltimore). 2022 Jul 15;101(28):e29599. doi: 10.1097/MD.0000000000029599. Medicine (Baltimore). 2022. PMID: 35838992 Free PMC article.
PCDH17 hypermethylation in cancerous and normal tissues was linked to shorter disease-specific survival (DSS, P = .026, P = .004), disease-free survival (DFS, P = .004, P = .019) while NEFH hypermethylation in cancerous tissues was related to shorter DSS (P = …
PCDH17 hypermethylation in cancerous and normal tissues was linked to shorter disease-specific survival (DSS, P = .026, P = .004), di …
CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z, Wang G, Li L. Su Z, et al. Cancer Biomark. 2023;38(2):143-159. doi: 10.3233/CBM-230028. Cancer Biomark. 2023. PMID: 37781794
BACKGROUND: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are common male diseases whose incidence rates gradually increase with age. ...RESULTS: We identified fifteen genes (CHRDL1, DES, FLNC, GSTP1, MYL9, TGFB3, NEFH, TAGLN, SPARCL1, SYNM, TRPM8, HP …
BACKGROUND: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are common male diseases whose incidence rates gradually inc …
A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients.
van Vlodrop IJH, Joosten SC, De Meyer T, Smits KM, Van Neste L, Melotte V, Baldewijns MMLL, Schouten LJ, van den Brandt PA, Jeschke J, Yi JM, Schuebel KE, Ahuja N, Herman JG, Aarts MJ, Bosman FT, Van Criekinge W, van Engeland M. van Vlodrop IJH, et al. Clin Cancer Res. 2017 Apr 15;23(8):2006-2018. doi: 10.1158/1078-0432.CCR-16-1236. Epub 2016 Oct 18. Clin Cancer Res. 2017. PMID: 27756787
These findings were confirmed in a third series of ccRCC cases from The Cancer Genome Atlas (HR, 3.60; 95% CI, 2.02-6.40).Conclusions: A four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts outcome of patients with ccRCC an …
These findings were confirmed in a third series of ccRCC cases from The Cancer Genome Atlas (HR, 3.60; 95% CI, 2.02-6.40).Conclusions …
Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer.
Calmon MF, Jeschke J, Zhang W, Dhir M, Siebenkäs C, Herrera A, Tsai HC, O'Hagan HM, Pappou EP, Hooker CM, Fu T, Schuebel KE, Gabrielson E, Rahal P, Herman JG, Baylin SB, Ahuja N. Calmon MF, et al. Epigenetics. 2015;10(7):622-32. doi: 10.1080/15592294.2015.1050173. Epigenetics. 2015. PMID: 25985363 Free PMC article.
Neurofilament heavy polypeptide (NEFH) has recently been identified as a candidate DNA hypermethylated gene within the functional breast cancer hypermethylome. ...Using a comprehensive approach, we studied the epigenetic inactivation of neurofilament genes in breast …
Neurofilament heavy polypeptide (NEFH) has recently been identified as a candidate DNA hypermethylated gene within the functional bre …
Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
Joosten SC, Deckers IA, Aarts MJ, Hoeben A, van Roermund JG, Smits KM, Melotte V, van Engeland M, Tjan-Heijnen VC. Joosten SC, et al. Epigenomics. 2017 Sep;9(9):1243-1257. doi: 10.2217/epi-2017-0040. Epub 2017 Aug 14. Epigenomics. 2017. PMID: 28803494 Review.
RESULTS: We identified promoter methylation of BNC1, SCUBE3, GATA5, SFRP1, GREM1, RASSF1A, PCDH8, LAD1 and NEFH as promising prognostic markers. Extensive methodological heterogeneity across the included studies was observed, which hampers comparability and reproducibility …
RESULTS: We identified promoter methylation of BNC1, SCUBE3, GATA5, SFRP1, GREM1, RASSF1A, PCDH8, LAD1 and NEFH as promising prognost …
Neurofilament heavy polypeptide regulates the Akt-beta-catenin pathway in human esophageal squamous cell carcinoma.
Kim MS, Chang X, LeBron C, Nagpal JK, Lee J, Huang Y, Yamashita K, Trink B, Ratovitski EA, Sidransky D. Kim MS, et al. PLoS One. 2010 Feb 3;5(2):e9003. doi: 10.1371/journal.pone.0009003. PLoS One. 2010. PMID: 20140245 Free PMC article.
RNA interference-mediated knockdown of NEFH accelerated ESCC cell growth in culture and increased tumorigenicity in vivo, whereas forced expression of NEFH significantly inhibited cell growth and colony formation. ...Cancer cells with methylated NEFH c …
RNA interference-mediated knockdown of NEFH accelerated ESCC cell growth in culture and increased tumorigenicity in vivo, whereas for …
Identification of co-regulated genes associated with doxorubicin resistance in the MCF-7/ADR cancer cell line.
Miri A, Gharechahi J, Samiei Mosleh I, Sharifi K, Jajarmi V. Miri A, et al. Front Oncol. 2023 Jun 15;13:1135836. doi: 10.3389/fonc.2023.1135836. eCollection 2023. Front Oncol. 2023. PMID: 37397367 Free PMC article.
INTRODUCTION: The molecular mechanism of chemotherapy resistance in breast cancer is not well understood. The identification of genes associated with chemoresistance is critical for a better understanding of the molecular processes driving resistance. ...Functional enrichm …
INTRODUCTION: The molecular mechanism of chemotherapy resistance in breast cancer is not well understood. The identification of genes …
Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.
Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, Hoshida Y, Llovet JM, Powers S. Revill K, et al. Gastroenterology. 2013 Dec;145(6):1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055. Epub 2013 Sep 5. Gastroenterology. 2013. PMID: 24012984 Free PMC article.
Subsequent validation led us to focus on functionally characterizing 2 candidates, sphingomyelin phosphodiesterase 3 (SMPD3) and neurofilament, heavy polypeptide (NEFH), which we found to behave as tumor suppressor genes in HCC. Overexpression of SMPD3 and NEFH by s …
Subsequent validation led us to focus on functionally characterizing 2 candidates, sphingomyelin phosphodiesterase 3 (SMPD3) and neurofilame …
Frequent promoter hypermethylation associated with human papillomavirus infection in pharyngeal cancer.
Nakagawa T, Matsusaka K, Misawa K, Ota S, Takane K, Fukuyo M, Rahmutulla B, Shinohara KI, Kunii N, Sakurai D, Hanazawa T, Matsubara H, Nakatani Y, Okamoto Y, Kaneda A. Nakagawa T, et al. Cancer Lett. 2017 Oct 28;407:21-31. doi: 10.1016/j.canlet.2017.08.008. Epub 2017 Aug 18. Cancer Lett. 2017. PMID: 28823962
We performed genome-wide DNA methylation analysis using an Infinium 450k BeadArray for clinical OPSCC and non-cancerous samples and cancer cell lines with/without 5-aza-2'-deoxycytidine and/or trichostatin A treatment. ...The methylation of nine genes (GHSR, ITGA4, …
We performed genome-wide DNA methylation analysis using an Infinium 450k BeadArray for clinical OPSCC and non-cancerous samples and …
Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer.
Fang Y, Wang Y, Zeng D, Zhi S, Shu T, Huang N, Zheng S, Wu J, Liu Y, Huang G, Xue Y, Bin J, Liao Y, Shi M, Liao W. Fang Y, et al. Oncoimmunology. 2021 Jul 16;10(1):1951019. doi: 10.1080/2162402X.2021.1951019. eCollection 2021. Oncoimmunology. 2021. PMID: 34345533 Free PMC article.
Tyrosine kinase inhibitors (TKI) play a pivotal role in the treatment of non-small-cell lung cancer (NSCLC) with mutations in epidermal growth factor receptor (EGFR) and rearrangements in anaplastic lymphoma kinase (ALK). ...However, no significant change in anti-tumor cel …
Tyrosine kinase inhibitors (TKI) play a pivotal role in the treatment of non-small-cell lung cancer (NSCLC) with mutations in epiderm …
37 results